Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Journal Articles

Platelet-Dependent Thrombin Generation Induced By ADP or Activated Factor X Does Not Contribute to Increased In Vivo Thrombin Formation in Myeloproliferative Neoplasms

Christina Berens, Heiko Rühl, MD, Jens Müller, Johannes Oldenburg, MD PhD, Peter Brossart, MD, Dominik Wolf, MD, Bernd Pötzsch

Blood (2018) 132 (Supplement 1): 4336.

https://doi.org/10.1182/blood-2018-99-118487

Published: 2018

Journal Articles

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD, Susan Halimeh, MD, Robert Klamroth, Joris Versteden, Martina Jansen, Larisa Belyanskaya, PhD

Blood (2018) 132 (Supplement 1): 5034.

https://doi.org/10.1182/blood-2018-99-116577

Published: 2018

Journal Articles

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

Beatrice Nolan, Johnny Mahlangu, Guy Young, Barbara A Konkle, K. John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Johannes Oldenburg, MD PhD, Keiji Nogami, MDPhD, Nikola Tripkovic, Huixing Yuan, Dan Rudin

Blood (2018) 132 (Supplement 1): 1192.

https://doi.org/10.1182/blood-2018-99-118586

Published: 2018

Journal Articles

Immune Tolerance Induction for FIX Inhibitors Using Combined B and T Cell Immune Modulation Therapy in Severe Hemophilia B

Yasmina L. Abajas, MD, Paul Edward Monahan, MD, Brenda Nielsen, RN, Pia Petrini, MD, Susanna Ranta, MD PhD, Geoffrey A. Allen, MD, Silvia Horneff, MD, Annika Martensson, MD PhD, Johannes Oldenburg, MD PhD, Rolf Ljung, MD PhD Professor

Blood (2018) 132 (Supplement 1): 1193.

https://doi.org/10.1182/blood-2018-99-120141

Published: 2018

Journal Articles

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Ri Liesner, Joris Versteden, Shannely Lowndes, Larisa Belyanskaya, PhD, Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD

Blood (2018) 132 (Supplement 1): 1204.

https://doi.org/10.1182/blood-2018-99-110608

Published: 2018

Journal Articles

Long-Term Follow-up of Hemophilia a Patients Who Previously Showed Complete or Partial Success in Immune Tolerance Induction Therapy with a Single Plasma-Derived FVIII/VWF Product: Long-Term ITI Study

Víctor Jiménez-Yuste, Dr, Johannes Oldenburg, MD PhD, Savita Rangarajan, MBBS, FRCP, FRCPath, Roser Peiró, PhD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 2282.

https://doi.org/10.1182/blood.V126.23.2282.2282

Published: 2015

Journal Articles

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

Guy Young, MD, Peter W. Collins, MD, Ramin Tehranchi, MD, PhD, Ampaiwan Chuansumrit, Hideji Hanabusa, MD, Steven R. Lentz, MD PhD, Johnny N. Mahlangu, MBBCh, MMed, FCPath, Evelien Mauser-Bunschoten, Claude Negrier, Johannes Oldenburg, MD PhD, Turkan Patiroglu, MD, Elena Santagostino, MD PhD, Marek Zak, Fara Abdul Karim

Blood (2014) 124 (21): 2846.

https://doi.org/10.1182/blood.V124.21.2846.2846

Published: 2014

Journal Articles

Characterization of Patients with Glanzmann Thrombasthenia and Identification of 17 Novel Mutations

Kirstin Sandrock-Lang, PhD, Johannes Oldenburg, MD PhD, Verena Wiegering, MD, Susan Halimeh, MD, Sentot Santoso, Karin Kurnik, Lars Fischer, Dimitrios Tsakiris, MD, Michael Sigl-Kraetzig, Brigit Brand, MD, Katharina Kraetzer, Niklas Deeg, Eileen Busse, Zieger Barbara

Blood (2014) 124 (21): 1460.

https://doi.org/10.1182/blood.V124.21.1460.1460

Published: 2014

Journal Articles

The Serpins C1-Inhibitor and Antithrombin Synergistically Regulate the Catalytic Life of Activated Factor XI in Healthy Individuals and Thrombophilic Patients

Heiko Rühl, MD, Jens Müller, PhD, Johannes Oldenburg, MD PhD, Bernd Pötzsch, MD PhD

Blood (2014) 124 (21): 1475.

https://doi.org/10.1182/blood.V124.21.1475.1475

Published: 2014

Journal Articles

New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency

Katsuyuki Fukutake, MD PhD, Manual Carcao, MD, Aida Inbal, MD, Bryce A. Kerlin, MD, Johannes Oldenburg, MD PhD, Anders Rosholm, MSc, PhD, May-Lill Garly, MD PhD, Diane J. Nugent, MD

Blood (2014) 124 (21): 1520.

https://doi.org/10.1182/blood.V124.21.1520.1520

Published: 2014

Journal Articles

Distribution of F8 Gene Mutations in 81 Inhibitor-Free, Severe Hemophilia a Patients with Full Exposure to FVIII

Anna Pavlova, MD PhD, Irina Matytsina, Morio Arai, MD, Johannes Oldenburg, MD PhD

Blood (2014) 124 (21): 1527.

https://doi.org/10.1182/blood.V124.21.1527.1527

Published: 2014

Journal Articles

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Jan Astermark, MD, PhD, John Schwarz, MA, Sharyne M. Donfield, PhD, Donna M. DiMichele, MD, Bruce M. Ewenstein, MD, PhD, Edward D. Gomperts, MD, George W. Nelson, PhD, Johannes Oldenburg, MD, PhD, Amy D. Shapiro, MD, Gerald Spotts, PhD, Cheryl A. Winkler, PhD, Erik Berntorp, MD, PhD

Blood (2009) 114 (22): 217.

https://doi.org/10.1182/blood.V114.22.217.217

Published: 2009

Journal Articles

Epitope Mapping of FIX Inhibitors Identify Contact Residues in the Protease Domain.

Sebastian Hoehl, Wolfhart Kreuz, MD, Nicole Krause, Diana Stichel, Inmaculada Martinez-Saguer, Christoph Kessel, Thomas Klingebiel, MD, Johannes Oldenburg, MD, PhD, James Irving, Christoph Königs

Blood (2009) 114 (22): 3172.

https://doi.org/10.1182/blood.V114.22.3172.3172

Published: 2009

Journal Articles

Establishment of an International Registry of Patients with Inherited FXIII Deficiency.

Vytautas Ivaskevicius, MD, Rainer Seitz, MD, PhD, Hans P. Kohler, MD, PhD, Laszlo Muszbek, PhD, Robert A.S. Ariens, PhD, Erhard Seifried, MD, PhD, Akitada Ichinose, PhD, Diane J. Nugent, MD, PhD, Johannes Oldenburg, MD, PhD

Blood (2007) 110 (11): 2149.

https://doi.org/10.1182/blood.V110.11.2149.2149

Published: 2007

Journal Articles

Five Novel Mutations in F13B Gene Resulting in FXIII Deficiency.

Vytautas Ivaskevicius, MD, Hannelore Rott, MD, Inge Scharrer, MD, PhD, Manuela Krause, MD, Erhard Seifried, MD, PhD, Johannes Oldenburg, MD, PhD

Blood (2007) 110 (11): 2150.

https://doi.org/10.1182/blood.V110.11.2150.2150

Published: 2007

Journal Articles

Pharmacogenetics of Oral Anticoagulation - VKORC1-Haplotypes Determine the Inter-Individual and Inter-Ethnical Variability.

Christof Geisen, MD, Matthias Watzka, PhD, Katja Sittinger, MD, Beate Luxembourg, MD, Michael Steffens, MD, Clemens R. Müller, PhD, Thomas F. Wienker, MD, PhD, Edelgard Lindhoff-Last, MD, PhD, Erhard Seifried, MD, PhD, Johannes Oldenburg, MD, PhD

Blood (2006) 108 (11): 719.

https://doi.org/10.1182/blood.V108.11.719.719

Published: 2006

Journal Articles

Effects of Pathogen Inactivation Using Amotosalen-UVA on Coagulation Parameters in Apheresis and Whole Blood Derived Frozen Plasma in a Large Blood Bank Setting.

Markus M. Mueller, MD, Hans-Ulrich Pfeiffer, Margaret Rheinschmidt, PhD, Bernd Poetzsch, MD, PhD, Johannes Oldenburg, MD, PhD, Laurence Corash, MD, PhD, Erhard Seifried, MD, PhD, Reinhard Henschler, MD, PhD

Blood (2006) 108 (11): 942.

https://doi.org/10.1182/blood.V108.11.942.942

Published: 2006

Journal Articles

Polymorphisms in the Promoter Region of the IL-10 Gene Is Associated with Inhibitor Development in Hemophilia A.

Jan Astermark, MD, PhD, Johannes Oldenburg, MD, PhD, Anna Pavlova, Erik Berntorp, MD, PhD, Ann-Kari Lefvert, MD, PhD, MIBS Study Group

Blood (2005) 106 (11): 212.

https://doi.org/10.1182/blood.V106.11.212.212

Published: 2005

Journal Articles

Mutations in the VKORC1 Gene Cause Warfarin Resistance, Warfarin Sensitivity and Combined Deficiency of Vitamin K Dependent Coagulation Factors.

Johannes Oldenburg, MD, PhD, Simone Rost, Andreas Fregin, PhD, Christof Geisen, Vytautas Ivaskevicius, MD, Erhard Seifried, MD, Inge Scharrer, MD, Maximilian Heistinger, MD, Edward Tuddenham, MD, Clemens Muller-Reible, PhD, Barbara Zieger, MD

Blood (2004) 104 (11): 277.

https://doi.org/10.1182/blood.V104.11.277.277

Published: 2004

NARROW

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Platelet-Dependent Thrombin Generation Induced By ADP or Activated Factor X Does Not Contribute to Increased In Vivo Thrombin Formation in Myeloproliferative Neoplasms

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

Immune Tolerance Induction for FIX Inhibitors Using Combined B and T Cell Immune Modulation Therapy in Severe Hemophilia B

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Long-Term Follow-up of Hemophilia a Patients Who Previously Showed Complete or Partial Success in Immune Tolerance Induction Therapy with a Single Plasma-Derived FVIII/VWF Product: Long-Term ITI Study

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

Characterization of Patients with Glanzmann Thrombasthenia and Identification of 17 Novel Mutations

The Serpins C1-Inhibitor and Antithrombin Synergistically Regulate the Catalytic Life of Activated Factor XI in Healthy Individuals and Thrombophilic Patients

New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency

Distribution of F8 Gene Mutations in 81 Inhibitor-Free, Severe Hemophilia a Patients with Full Exposure to FVIII

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Epitope Mapping of FIX Inhibitors Identify Contact Residues in the Protease Domain.

Establishment of an International Registry of Patients with Inherited FXIII Deficiency.

Five Novel Mutations in F13B Gene Resulting in FXIII Deficiency.

Pharmacogenetics of Oral Anticoagulation - VKORC1-Haplotypes Determine the Inter-Individual and Inter-Ethnical Variability.

Effects of Pathogen Inactivation Using Amotosalen-UVA on Coagulation Parameters in Apheresis and Whole Blood Derived Frozen Plasma in a Large Blood Bank Setting.

Polymorphisms in the Promoter Region of the IL-10 Gene Is Associated with Inhibitor Development in Hemophilia A.

Mutations in the VKORC1 Gene Cause Warfarin Resistance, Warfarin Sensitivity and Combined Deficiency of Vitamin K Dependent Coagulation Factors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only